China Tracker - Details for Weikang Bio-Technology (WKBT)


Warning: fopen(http://finance.yahoo.com/d/quotes.csv?s=WKBT&f=snl1a2xf6): failed to open stream: HTTP request failed! HTTP/1.0 403 Forbidden in /home/fixyou/public_html/tracker_details.php on line 58

Warning: fgetcsv() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 60

Warning: fclose() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 61
 Weikang Bio-Technology
Shares Outstanding (MRQ): 32.48 mill 
New Shares / Dilution (TTM): 4.45 mill15.89% 
Cash (MRQ): 61.60 mill0.00%
Account Receivables (MRQ): 2.86 mill0.00%
Account Receivables (Q/Q): + 2.34 mill  
Long-Term Debt (MRQ): 3.50 mill0.00%
Revenue Growth (Q/Q): -39.40% 
Revenue Growth (Y/Y): 62.62%
Net Income Growth (Q/Q): -66.89% 
Net Income Growth (Y/Y): 95.25%
EPS Growth (Y/Y): 68.47%
Net Margin (Q/Q): 21.9% (40.2%)-18.20% 
Net Margin (Y/Y): 21.9% (18.3%)3.70% 
EPS | P/E (2 MRQ Projection): $0.930.00 
CFPS | P/CF (2 MRQ Projection): $0.520.00 
Price/Sales (2 MRQ Projection): 0.00
Price/Book (MRQ): 0.00 
Auditor: Samuel H. Wong & Co.
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2011-08-16): $0.950.00 
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Reverse Merger on 2007-12-07 

 Business Outlook

The Audit Committee of the Board of Directors today announced that Grant Thornton (GT) has verified that the cash amounts listed on the Company's SEC filings for 2010 and the first quarter of 2011 are consistent with account statements obtained from WKBT's banks directly by GT.

(Source: PR Newswire, 2011-06-07)

Our market share continues to improve with our successful new product launches and expanded sales channels. The five new products we launched during 2010 contributed roughly $11 million to our total sales, and we plan to launch four new products during 2011, three of which we expect to roll out during the first quarter. We are committed to implementing improved marketing and promotional strategies as well as aggressive R&D, both of which contributed to our strong performance this year. Furthermore, we have streamlined our cost structure in order to provide the highest quality product at the best value, and we look forward to continued growth of this nature as we continue to pursue additional US investor support and interaction in 2011.

(Source: PR Newswire, 2011-03-22)

Our decision to bring on additional sales staff last quarter has proven to be very beneficial to our marketing and distribution efforts and overall growth strategy. In November, we estimated that our new agents in Changsha, Nanning, and Zhuzhou would bring in annual revenue of roughly $15 million, and we are pleased that they are already on track to exceed our original projections. The exceptional effort from our entire sales team has allowed us to maximize the effectiveness of our recent product launches and increased advertising investment in the second half of 2010, driving dramatic growth beyond our expectations in both sales and profit for the fourth quarter and fiscal 2010.

(Source: PR Newswire, 2011-01-24)

    see all Business Outlook notes

 Investor Presentations
2011-04-01 (PDF)   DOWNLOAD (right click, save as)
2010-07-13 (HTML)   VIEW
WKBT
Healthcare & Drugs
SCORE
5
READ: Score Cards Explained
SAFETY/RISK SCORE
HIGH RISK
DETAILS: Safety/Risk Model for WKBT
Current Price:  n/a
F10k Day (2009-08-10): -100.00%$2.00
2009 Close: -100.00%$2.50
2010 Close: -100.00%$2.95
2011 Close: -100.00%$0.48
High (2012-02-23): -100.00%$0.44
Low (2012-07-02): -100.00%$0.16
Exchange:
Market Capitalization: n/a
Total Shares: 32.48 mill
Float: n/a
Avg Volume: n/a
Last Quarter: 2011-06-30
Revenue (MRQ): 17.06 mill
Net Income (MRQ): 3.74 mill
Op. Cash Flow (MRQ): -2.19 mill
all financial data provided without warranty